UAE approves new Diabetes treatment
Dubai, November 13, 2011
The UAE Ministry of Health has become the second regulatory authority in the world to register Eli Lilly's exenatide prolonged release suspension (Bydureon) treatment for type 2 diabetes.
Exenatide is the first and only once weekly therapy for the treatment of Type 2 Diabetes. It is an extended release medication designed to deliver a steady plasma concentration of exenatide in a single weekly dose.
Announcing this at a press conference on Sunday, the officials highlighted Lilly’s commitment to advance innovation in the diabetes field and the ministry's commitment in providing the latest solutions to patients with diabetes in the UAE to help them reach their treatment goals.
The UAE approval marks second registration worldwide after the European Commission. Bydureon is the first once-weekly treatment for type 2 diabetes, they added.
“We are proud to be able to make available, to patients, doctors and healthcare professionals an innovative treatment for diabetes within few months of being registered in Europe,” said Huzur Devletsah – general manager of Lilly for the Gulf Area.
“This is only possible through effective collaboration and engagement of the ministry of health to advance patient care in the field of diabetes,” he noted.
Joachim Becker- senior advisor- diabetes strategy – Lilly Emerging Markets, "It will answer an important unmet need for patients and healthcare professionals."
“Importantly, exenatide for prolonged release suspension will help patients achieve better glycaemic control in single weekly dose – giving them added confidence and freedom while managing type 2 diabetes.”
"Exenatide prolonged release provides glyacemic control whenever blood glucose levels are elevated, offering the potential for improved HBA1C control with the added benefit of weight loss occurring in most patients," he explained.
Exenatide prolonged release is a once-weekly formulation of exenatide, the active in exenatide twice daily injection, which has been available in the US since 2005 and in Europe since 2007.
It is being used by more than 1.8 million patients in 70 countries worldwide to improve glycaemic control in adults with type 2 diabetes.-TradeArabia News Service
More Health & Environment Stories
- The age of genomic medicine dawns, finally
- Over 300 exhibitors for Saudi healthcare event
- Mackeen unveils document management solution
- Seha opens new clinics in Abu Dhabi, Al Ain
- SARS virus claims one more victim in Saudi
- New support group comes to overeaters' rescue
- RAK Hospital launches urinary clinic for women
- NBAD backs Emiratis on Antarctica trip
- Cut sugar intake drastically urges WHO
- Al khaliji to fund Qatar recycling plant
- Qatar researcher in 360km breast cancer run
- New facilitator to open in DHCC
- Many countries lack capacity to prevent hearing loss
- QUIT NOW: Passive smoking hurts kids' arteries
- San Francisco to ban plastic water bottles
- GSK wins home toothpaste award for Sensodyne
- E-integration vital to GCC healthcare industry
- Fakih IVF unveils two new genetic tests
- 2 die from H1N1 in Oman
- Al Noor Hospitals targets domestic growth
- Medical panel on the way in Bahrain
- 40pc of UAE adults ‘have hypertension’
- Saudi diabetics urged to stay away from camels
- GCC readies plan to fight heart diseases
- Bahrain opens sickle cell hospital
- Hazardous waste focus for Oman summit
- Infectious viruses to be tracked by satellite in UAE
- Mafraq Hospital names new surgery chief
- Saudi health ministry seals BMJ partnership
- Need for medical simulation training highlighted